206
Participants
Start Date
October 31, 2009
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Bortezomib
Bortezomib IV
Rituximab
Rituximab IV
Cyclophosphamide
Cyclophosphamide IV
Doxorubicin
Doxorubicin IV solution
Vincristine
Vincristine IV
Prednisone
Prednisone tablet
St. Luke's- Roosevelt Medical Center, New York
UPMC Cancer Center, Pittsburgh
Hematology and Oncology Associates of NEPA, Dunmore
Guthrie Clinic, Sayre
Berks Hematology Oncology Associates, West Reading
Holy Cross Hospital, Silver Spring
Sinai Hospital of Baltimore, Baltimore
St. Agnes Hospital of Baltimore, Baltimore
Virginia Cancer Institute, Richmond
Raleigh Hematology Oncology Associates P.C., Raleigh
South Carolina Oncology Associates, PA, Columbia
Winship Cancer Institute at Emory University, Atlanta
Georgia Cancer Specialists, Atlanta
Dublin Hematology and Oncology, Dublin
Sharp Healthcare, San Diego
Coastal Oncology, PL, Ormond Beach
Florida Cancer Specialists & Research Institute, Gainsville
MD Anderson Cancer Center of Orlando, Orlando
Alves/ Domenech Oncology-Hematology Clinic, Hollywood
Florida Cancer Specialists, Fort Myers
Florida Cancer Institute ATI, New Port Richey
Tennessee Oncology, Nashville
Chattanooga Oncology and Hematology Associates, PC, Chattanooga
Summa Health System, Akron
Oncology Hematology Care, Cincinnati
Central Indiana Cancer Centers, Fishers
Cancer Care Center Inc. P.C., New Albany
Barbara Ann Karmanos Cancer Institute, Detroit
Mid Michigan Physicians, Lansing
Iowa Oncology Research Association, Des Moines
Siouxland Hematology and Oncology Associates LLP, Sioux City
Iowa Blood and Cancer Care, Cedar Rapids
Duluth Clinic, Duluth
St. Luke's Hospital Cancer Care Center, Duluth
Rush University Medical Center, Chicago
Saint Luke's Cancer Institute, Kansas City
Missouri Cancer Associates, Columbia
Kansas City Cancer Center, LLC, Overland Park
Tyler Cancer Center, Tyler
US Oncology- Central Drug, Fort Worth
US Oncology- Central Laboratory, Fort Worth
Texoma Cancer Center, Wichita Falls
Oncology Consultants P.A., Houston
Oncology Consultants, Houston
US Oncology- Central Regulatory, The Woodlands
Texas Oncology Cancer Center, Austin
Rocky Mountain Cancer Center, Denver
University of Southern California, Los Angeles
Jonsson Comprehensive Cancer Center, Los Angeles
Tower Cancer Research Foundation, Beverly Hills
Oncology Care Medical Associates, Montebello
Wilshire Oncology Medical Group, Rancho Cucamonga
Moores Cancer Center- UCSD, La Jolla
Loma Linda University Cancer Center, Loma Linda
Fountain Valley Regional Hospital, Fountain Valley
St. Jude Heritage Healthcare, Fullerton
Central Coast Medical Oncology Corporation, Santa Maria
Antelope Valley Cancer Center, Lancaster
Bay Area Cancer Research Group, Pleasant Hill
Kaiser Group Health, Portland
Puget Sound Cancer Centers, Edmonds
Northwest Cancer Specialists PC, Vancover
TORI- Central Pharmacy, Los Angeles
TORI- Central Regulatory, Los Angeles
Cornell, New York
Lahey Clinic Medical Center, Burlington
Berkshie Hematology Oncology, Pittsfield
Hackensack University Medical Center, Hackensack
Hematology/Oncology Associates of Northern New Jersey, P.A., Morristown
Hematology Oncology Associates of South Jersey, Mount Holly
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY